Unichem Laboratories Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Pabitrakumar Bhattacharyya

Chief Executive Officer (CEO)

₹29.2m

Compensación total

Porcentaje del salario del CEO	64.3%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	12yrs
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Feb 06

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Jul 23

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 15

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 01

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Nov 27

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Jun 05

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

Mar 02

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

Feb 09

Should You Take Comfort From Insider Transactions At Unichem Laboratories Limited (NSE:UNICHEMLAB)?

Jan 19

Do Institutions Own Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares?

Dec 29

Is Unichem Laboratories (NSE:UNICHEMLAB) Weighed On By Its Debt Load?

Dec 10

Key Things To Understand About Unichem Laboratories' (NSE:UNICHEMLAB) CEO Pay Cheque

Nov 23

Did Unichem Laboratories' (NSE:UNICHEMLAB) Share Price Deserve to Gain 41%?

Nov 02

Should You Buy Unichem Laboratories Limited (NSE:UNICHEMLAB) For Its 1.5% Dividend?

Oct 13

How Much Are Unichem Laboratories Limited (NSE:UNICHEMLAB) Insiders Spending On Buying Shares?

Sep 16

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Too Much Debt?

Aug 26

Is Unichem Laboratories Limited's (NSE:UNICHEMLAB) Shareholder Ownership Skewed Towards Insiders?

Aug 05

Would Shareholders Who Purchased Unichem Laboratories'(NSE:UNICHEMLAB) Stock Three Years Be Happy With The Share price Today?

Jul 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pabitrakumar Bhattacharyya en comparación con los beneficios de Unichem Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	₹29m	₹19m	-₹705m

Compensación vs. Mercado: La compensación total de Pabitrakumar($USD347.62K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD265.63K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Pabitrakumar con los resultados de la empresa.

CEO

Pabitrakumar Bhattacharyya (55 yo)

less than a year

Permanencia

₹29,175,000

Compensación

Mr. Pabitrakumar Kalipada Bhattacharyya serves as a Managing Director and Director at Unichem Laboratories Limited since August 10, 2023. Mr. Bhattacharyya brings rich experience from organizations like Su...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pabitrakumar Bhattacharyya	MD & Director	less than a year	₹29.18m	sin datos
Pradeep Bhandari	Head of Legal	5yrs	₹9.84m	sin datos
Prasad Joshi	Vice President of Human Resources & ER	16.2yrs	₹7.48m	sin datos
Vinod Behl	Head of Projects & Investments	no data	₹2.10m	sin datos
Jalesh Burye	Chief Quality & Compliance Officer	no data	sin datos	sin datos
Dhananjay Sathe	Chief Scientific & Compliance Officer	no data	sin datos	sin datos
Ashwani Kumar	Chief Manufacturing & Compliance Officer	no data	sin datos	sin datos
Bhagwat Dhingra	Chief Executive of Domestic Pharma	12yrs	₹13.62m	sin datos
Scott Delaney	President of North America & CEO of North America	6.2yrs	sin datos	sin datos
P. Deshpande	Vice President of Chemical of Research and Development	no data	₹593.35k	sin datos
Gajendra Ghanekar	Vice President of Commercial	23.8yrs	₹6.14m	sin datos
R. Shapeti	Advisor of Active Pharmaceutical Ingredients (API)	no data	₹5.24m	sin datos

12.0yrs

Permanencia media

65.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de UNICHEMLAB es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pabitrakumar Bhattacharyya	MD & Director	less than a year	₹29.18m	sin datos
Prakash Mody	Chairman	50.2yrs	₹328.40m	16.21% ₹ 6.6b
Arun Todarwal	Independent Director	less than a year	₹100.00k	sin datos
Pranay Godha	Non-Executive Non-Independent Director	less than a year	₹300.00k	sin datos
Priti Puri	Additional Independent Non-Executive Director	1.4yrs	₹850.00k	sin datos
Anand Kusre	Independent Director	less than a year	₹100.00k	sin datos

1.0yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de UNICHEMLAB no se considera experimentada (1 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Unichem Laboratories Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Recent updates

Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024

High number of new directors

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

New major risk - Revenue and earnings growth

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Debt Sensibly?

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Does Unichem Laboratories (NSE:UNICHEMLAB) Have A Healthy Balance Sheet?

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Unichem Laboratories (NSE:UNICHEMLAB) Is Due To Pay A Dividend Of ₹4.00

Upcoming dividend of ₹4.00 per share

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

New 90-day high: ₹295

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA

Unichem Laboratories Limited to Report Q3, 2021 Results on Jan 30, 2021

Should You Take Comfort From Insider Transactions At Unichem Laboratories Limited (NSE:UNICHEMLAB)?

New 90-day high: ₹286

Unichem Laboratories Limited Receives ANDA Approval from USFDA for Unichem's Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, and 400 Mg